Stemtech Reports Q1 Loss Amid 450% Share Dilution, Going Concern Warning, and Control Weaknesses
Summary
Stemtech Corp reported a significant Q1 revenue decline and a worsening working capital deficit, alongside a massive 450% increase in shares outstanding since year-end 2025. The company maintains a 'going concern' warning and disclosed material weaknesses in internal controls.
Key Events
-
Massive Share Dilution
Shares outstanding increased by over 450% from 425.98 million at December 31, 2025, to 2.37 billion as of June 22, 2026. This includes 886.94 million shares issued for $152,516 in convertible debt conversions at a 30% discount, and 336.89 million shares issued for services valued at $67,379.
-
Continued Going Concern Warning
The company continues to report recurring net losses and negative cash flows, with a working capital deficiency of $10.5 million, raising substantial doubt about its ability to continue as a going concern.
-
Significant Revenue Decline
Net sales for Q1 2026 decreased by 43.1% to $462,957, down from $868,046 in Q1 2025, primarily due to reduced inventory availability.
-
Material Weaknesses in Internal Controls
Management concluded that disclosure controls and procedures were not effective as of March 31, 2026, due to material weaknesses in internal control over financial reporting.
Analysis
Stemtech Corp's first-quarter report reveals a company in severe financial distress, marked by a substantial 43.1% year-over-year revenue decline and a worsening working capital deficit. The most critical development is the massive dilution, with shares outstanding increasing by over 450% since December 31, 2025, primarily due to issuing shares for services and converting convertible debt at a discount. The company continues to operate under a 'going concern' warning, indicating significant doubt about its ability to continue operations. Furthermore, management disclosed material weaknesses in internal controls over financial reporting, a serious governance red flag. While the net loss slightly improved, and the company secured $2.5 million in financing post-quarter for inventory, these are minor offsets against the backdrop of fundamental operational and financial challenges, including a stock price at its 52-week low.
At the time of this filing, STEK was trading at $0.00 on OTC in the Trade & Services sector, with a market capitalization of approximately $433.9K. The 52-week trading range was $0.00 to $0.03. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.